Investors and Partners
The company is actively supported by a solid network of financial, scientific and industrial partners.
VitamFero has successfully conducted several private placements. The company's shares are currently held by its founders, a group of business angels, Parisian and regional seed and venture capital funds and family and industrial funds.
- Aenean eget mi eget
- Sed arcu eros lacinia
- Duis dictum purus
- Integer sodales justo
- Etiam in sem et lectus
- Financial partners
The company is supported by many regional and national organizations commited to promoting innovation (i.e. BPI France, FranceAgriMer Atlanpole Biotherapy, Polepharma ...), by local authorities (Région Centre Val de Loire, département Indre & Loire) and by the European Union. ..
- Scientific partners
VitamFero concluded and continues to build science partnerships. Historically, the vaccine technology, largely developed by VitamFero has since been developed and patented jointly by the CNRS, INRA and François Rabelais University of Tours. It has also developed partnerships with the Institut Pasteur, Cellectis Agrosup Dijon and the University of Bourgogne (Dijon).
- Industrial partners
Recently VitamFero concluded an industrial partnership with the Australian company Bioproperties to ensure the launch of its first product: the vaccine against ovine toxoplasmosis which registration is scheduled from 2019 in New Zealand.